Valuation: Endonovo Therapeutics Inc

Market Cap 2.77M 2.43M 2.24M 2.09M 3.94M 264M 4.02M 26.96M 10.44M 129M 10.41M 10.19M 450M P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 9.93M 8.72M 8.02M 7.48M 14.1M 944M 14.38M 96.49M 37.38M 463M 37.27M 36.46M 1.61B EV / Sales 2021
112,421,804x
EV / Sales 2022 78,689,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 61 29/02/2012
Investor Relations Contact - 30/04/2014
Corporate Officer/Principal 77 29/11/2022
Director TitleAgeSince
Chairman 61 29/02/2012
Change 5-day change 1-year change 3-year change Capi.($)
+1.81%+3.35%+72.72%+131.25% 56.21B
+0.55%+8.49%+77.09%+100.93% 55.38B
+0.93%+4.11%-12.64%-12.98% 23.75B
+0.36%+3.42%+9.61%+407.11% 23.19B
+3.64%+8.34%+39.81%-5.88% 18.14B
+1.54%+6.04%+40.82%-29.62% 16.84B
+1.49%+17.24%+174.91%+344.55% 15.86B
-0.83%+2.06%+23.70%+182.37% 13.56B
+7.20%+13.33%+42.13% - 12.97B
Average +1.84%+6.94%+52.02%+139.72% 26.21B
Weighted average by Cap. +1.52%+6.60%+56.51%+132.02%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.06 0.1 6.95 0.11 0.71 0.28 3.41 0.27 0.27 11.87 0.14 0.12 0.11 0.1 0.19 12.87 0.2 1.32 0.51 6.32 0.51 0.5 21.98
Net income -3.1M -2.73M -2.51M -2.34M -4.41M -295M -4.5M -30.18M -11.69M -145M -11.66M -11.41M -504M -18.47M -16.22M -14.93M -13.91M -26.24M -1.76B -26.77M -180M -69.58M -862M -69.37M -67.87M -3B
Net Debt 7.1M 6.23M 5.73M 5.34M 10.08M 675M 10.28M 68.97M 26.72M 331M 26.64M 26.06M 1.15B 7.15M 6.28M 5.78M 5.39M 10.16M 680M 10.37M 69.53M 26.94M 334M 26.86M 26.28M 1.16B
Logo Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
-